Brain Tumors Clinical Trial
Official title:
Assessment of Sleep Complaints in Brain Tumor Survivors
Survivors of pediatric brain tumors are noted to have increased rates of excessive daytime
sleepiness. However, very little data are available regarding the specific sleep
disturbances of pediatric brain tumor survivors. Children ages 8 to 18 years of age who are
at least 5 years from diagnosis and at least 2 years post treatment or observation only for
a brain tumor will be targeted to assess the prevalence of sleep complaints.
The study focuses on the following objectives:
- To estimate sleep disturbance in a cohort of pediatric brain tumor survivors.
- Estimate the rates of parent- and self-reported excessive daytime sleepiness in
pediatric brain tumors
- Estimate the rates of parent-reported sleep-disordered breathing, including snoring and
witnessed apneas, in pediatric brain tumor survivors
- Estimate the rates of parent- and self-reported behavioral sleep problems, including
nocturnal enuresis, bedtime resistance, nighttime awakenings, nightmares, and fatigue
in pediatric brain tumor survivors.
The Study focuses on the following secondary objectives:
- To describe bedtime patterns and sleep hygiene of pediatric brain tumor survivors.
- Estimate the typical parent- and self-reported weekday sleep duration of pediatric
brain tumor survivors
- Estimate the typical parent- and self-reported weekend sleep duration of pediatric
brain tumor survivors and if it differs from the weekday sleep duration
- Estimate the typical parent- and self-reported consistency of sleep hygiene in
pediatric brain tumor survivors
This non-therapeutic single arm study will characterize the prevalence and types of sleep
complaints of pediatric brain tumor survivors. Brain tumor survivors ages 8 to 18 years who
are at least 5 years post diagnosis and 2 years post active therapy and their
parents/guardians will be approached to participate during clinic visits. If the patient and
guardian agree to participate, they will be administered three questionnaires in the clinic
during the patient's visit. From the medical record, the following variables will be
utilized to characterize the subjects and estimate which groups are at greatest risk of
sleep disturbances:
- Specific brain tumor diagnosis
- Location of tumor (cerebral hemispheres, parasellar region, posterior fossa, or spine)
- Age at diagnosis
- Obesity status
- Treatment modality (surgery, radiation therapy, and/or chemotherapy vs. observation
only)
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Completed |
NCT02537106 -
A Comparison of the Effect of 1.5 Versus 3% NaCl on Brain Relaxation and Microcirculation
|
N/A | |
Completed |
NCT01951950 -
Nicardipine vs Esmolol Craniotomy Emergence
|
Phase 1 | |
Completed |
NCT01222780 -
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
|
Phase 1 | |
Completed |
NCT00873184 -
Study of Massage Therapy Within a Brain Tumor Setting
|
N/A | |
Active, not recruiting |
NCT01115777 -
Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
|
||
Completed |
NCT00003935 -
Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
|
Phase 1 | |
Completed |
NCT00724191 -
Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)
|
||
Recruiting |
NCT04128306 -
Brain Areas of Time-To-Contact Perception: an Awake Surgery Study
|
N/A | |
Recruiting |
NCT05202899 -
Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy
|
Phase 4 | |
Completed |
NCT00707343 -
[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00850278 -
Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors
|
N/A | |
Completed |
NCT00528437 -
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
|
Phase 2 | |
Terminated |
NCT00107471 -
Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
|
Phase 1/Phase 2 | |
Completed |
NCT00187174 -
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
|
Phase 1 | |
Completed |
NCT00135876 -
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
|
Phase 3 | |
Completed |
NCT00062478 -
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
|
Phase 2 | |
Completed |
NCT00241670 -
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
|
Phase 3 | |
Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
Terminated |
NCT01018290 -
Navigated Transcranial Magnetic Stimulation in Tumor Surgery
|
N/A |